Skip to main content

New Government Commission Could Streamline Diabetes Care


July 30, 2012 — Two US senators have introduced an act that would ensure a thorough review of the US government's approach to diabetes care, an effort experts hope will ultimately slow the pace of this burgeoning epidemic. Several major medical associations were quick to applaud the bipartisan effort, which came out of the Senate Diabetes Caucus and its cochairs, senators Jeanne Shaheen (D-NH) and Susan Collins (R-Maine).
If approved, the National Diabetes Clinical Care Commission Act will create a public–private sector commission to recommend improvements to care.
"This is a fabulous idea when it comes to diabetes," Joan Salge Blake, RD, LDN, a spokesperson for the Academy of Nutrition and Dietetics, said to Medscape Medical News. "Prevention is key, it's absolutely key. Diabetes is the number 7 killer of Americans, and it's something we have a good chance of preventing. But more and more Americans are getting diabetes, and so many issues go along with it, kidney problems, eyesight issues, so many other health issues."
The Juvenile Diabetes Research Foundation (JDRF) also supports the commission formation. "As [the] national cost of diabetes [continues] to rise, it makes sense to ensure federal resources for diabetes care are leveraged most effectively and efforts are well coordinated so that patients receive the best possible care," Cynthia Rice, vice president, government relations, for JDRF said in an email to Medscape Medical News.
"There is a recognition in the diabetes community that continuation of the status quo is unacceptable," Alan Garber, MD, PhD, president of the American Association of Clinical Endocrinologists (AACE), said in a news release. "Doing nothing or even doing more of the same will not reverse the arc of worsening diabetes prevalence and complications which will ultimately overwhelm the entire healthcare system with devastating numbers of patients with this disease alone."
The National Diabetes Clinical Care Commission Act was introduced in September in the US House of Representatives and today has 26 cosponsors, including members of the Physician Caucus.
Under the Senate bill, the National Diabetes Clinical Care Commission will include healthcare professionals who work with patients with diabetes, as well as patient advocates and representatives of federal agencies involved with diabetes care. The group is to make recommendations to the US Secretary of Health and Human Services and to Congress.
The act is endorsed by the major diabetes organizations, including the Pediatric Endocrine Society, the Endocrine Society, the American Academy of Ophthalmology, and the American Diabetes Association, in addition to the AACE and JDRF.
The number of patients with type 2 diabetes in the United States has been growing unchecked in recent decades, roughly at pace with increasing obesity. The US Centers for Disease Control and Prevention (CDC) predicts that 1 in 3 children born in 2000 will develop the disease in their lifetime. Some 26 million Americans have diabetes today, the CDC says, and another 79 million have prediabetes, which greatly predisposes them to developing the disease. In the last 3 years alone, the number of people diagnosed with diabetes jumped by 2 million, and the number with prediabetes grew by 22 million, the CDC says.
In addition, data from the CDC and National Institutes of Health show that incidence of type 1 diabetes also is rising rapidly among youth, with a 23% increase from 2001 to 2009, JDRF's Rice wrote in her email.
Diabetes care costs the United States $174 billion per year, including a third of all Medicare spending.
"AACE believes the National Diabetes Clinical Care Commission is a significant first step in the nation's battle against diabetes and its consequences," Dr. Garber said in a news release.
 

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more